Loading...
•
Jun 30
Owens & Minor Q2 2025 Earnings Report
Reported higher revenue in continuing operations but posted a net loss due to large transaction-related charges; adjusted earnings and EBITDA improved.
Key Takeaways
Owens & Minor delivered Q2 2025 revenue growth in continuing operations, driven by Patient Direct performance. Despite improved adjusted operating income and adjusted EBITDA, the company reported a significant GAAP net loss due to transaction breakage fees and discontinued operations charges. The Products & Healthcare Services segment was classified as discontinued operations.
Revenue from continuing operations grew to $681.9M from $660.4M last year
GAAP net loss from continuing operations was $83.8M, or $(1.09) per share
Adjusted EPS from continuing operations was $0.26, up from $0.25 last year
Adjusted EBITDA increased to $96.6M from $91.1M
Owens & Minor
Owens & Minor
Forward Guidance
The company will provide 2025 financial outlook for continuing operations during the earnings call, focusing on growth in Patient Direct and the pending sale of the Products & Healthcare Services segment.
Positive Outlook
- Revenue growth in continuing operations
- Adjusted operating income and EBITDA improved year-over-year
- Patient Direct segment performance remained strong
- Company positioned as a pure-play Patient Direct business post-divestiture
- Favorable demographic trends expected to support long-term growth
Challenges Ahead
- Large GAAP net loss due to transaction breakage fee and discontinued operations charges
- Significant transaction-related and financing costs
- Higher net capital expenditures
- Operating cash flow declined significantly from prior year
- Business transition risk with segment divestiture